Medicus Pharma Ltd. (MDCX) has officially submitted an application to the U.S. Food and Drug Administration (FDA) seeking orphan drug designation for its innovative drug Skinject®, with the indication for Gorlin Syndrome (Basal Cell Nevus Syndrome).

Kevin Hassett, Director of the White House National Economic Council, stated that the recent substantial decline in technology stocks does not indicate a comprehensive sell-off risk for the AI industry. He acknowledged that some enterprises are indeed burdened with significant debt, which warrants attention. However, he also pointed out that there are many financially strong companies within the industry that hold both equity and debt in related firms; these companies may be poised to acquire or provide funding support when opportunities arise.